» Articles » PMID: 3540517

Lead Intoxication

Overview
Journal Med Toxicol
Specialty Toxicology
Date 1986 Nov 1
PMID 3540517
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Lead intoxication was recognised as early as 2000 BC and the widespread use of lead has been a cause of endemic chronic plumbism in several societies throughout history. In the twentieth century, lead intoxication is still a common problem. In children it is largely due to ingestion of pica and environmental exposure, whereas adult groups at greatest risk are the industrially exposed: thus, screening of these workers should be undertaken at regular intervals. The clinical features of lead intoxication are nonspecific and often go unrecognised. The early manifestations are largely neuropsychiatric, followed by more significant disturbances of the central and peripheral nervous systems, symptomatic gastrointestinal, musculoskeletal, haematological and endocrine abnormalities. The association of lead poisoning with renal disease is well documented and must be considered, particularly if there is associated hypertension and/or gout. Blood lead concentrations are an unreliable predictor of body lead stores as they are indicative only of recent exposure. Haematological parameters have been used to assess those at risk of toxicity, but although more reliable than blood concentrations, they also fail to predict those patients at risk of toxicity. The recommended assessment for patients with suspected lead intoxication is a calcium disodium edetate chelation test, which is a sensitive marker for assessing body stores and subsequent intoxication. In children the dosage should be 50 mg/kg up to 1000 mg, and in adults 1000 mg administered intravenously or 2000 mg intramuscularly in divided doses 12 hours apart with subsequent 72 hour urinary lead estimations. Lead excretion levels greater than 350 micrograms/72 hours should be considered as suggestive of intoxication, particularly if supported by historical, clinical or biochemical evidence of lead exposure. Treatment of patients with positive chelation tests involves symptomatic treatment and a course of chelation therapy utilising calcium disodium edetate in doses similar to those used for testing, and in the more severely intoxicated patient, the addition of dimercaprol in doses of 75 mg/m2 every 4 hours to a total of 300 mg/m2/day. The safety of these treatment regimens is well documented.

Citing Articles

The Gilded Clot: Review of Metal-Modulated Platelet Activation, Coagulation, and Fibrinolysis.

Nielsen V, Goff T, Hunsaker B, Neves C Int J Mol Sci. 2023; 24(4).

PMID: 36834712 PMC: 9966405. DOI: 10.3390/ijms24043302.


Dynamic transcriptome landscape of Paragonimus proliferus developmental stages in the rat lungs.

Li S, Yang Y, Li J, Wu K, Chang G, Hua L Parasitol Res. 2021; 120(5):1627-1636.

PMID: 33792812 DOI: 10.1007/s00436-021-07111-0.


Chronic low-level lead exposure. Its role in the pathogenesis of hypertension.

Sharp D, Becker C, Smith A Med Toxicol. 1987; 2(3):210-32.

PMID: 3298924 DOI: 10.1007/BF03259865.


Pharmacokinetics and toxicity of bismuth compounds.

Slikkerveer A, de Wolff F Med Toxicol Adverse Drug Exp. 1989; 4(5):303-23.

PMID: 2682129 DOI: 10.1007/BF03259915.


Lead encephalopathy from an imported Toby mug.

Zuckerman M, Savory D, Rayman G Postgrad Med J. 1989; 65(763):307-9.

PMID: 2608565 PMC: 2429294. DOI: 10.1136/pgmj.65.763.307.

References
1.
LILIS R, Fischbein A, Valciukas J, BLUMBERG W, SELIKOFF I . Kidney function and lead: relationships in several occupational groups with different levels of exposure. Am J Ind Med. 1980; 1(3-4):405-12. DOI: 10.1002/ajim.4700010318. View

2.
Graziano J . Role of 2,3-dimercaptosuccinic acid in the treatment of heavy metal poisoning. Med Toxicol. 1986; 1(3):155-62. DOI: 10.1007/BF03259834. View

3.
Fortenberry J . Gasoline sniffing. Am J Med. 1985; 79(6):740-4. DOI: 10.1016/0002-9343(85)90525-x. View

4.
Wedeen R . Occupational renal disease. Am J Kidney Dis. 1984; 3(4):241-57. DOI: 10.1016/s0272-6386(84)80041-4. View

5.
BALL G, Sorensen L . Pathogenesis of hyperuricemia in saturnine gout. N Engl J Med. 1969; 280(22):1199-202. DOI: 10.1056/NEJM196905292802203. View